Yinghong Wang, MD, PhD, from The University of Texas MD Anderson Cancer Center, discusses the challenges in implementing fecal transplantation for treating immunotherapy-induced colitis. Currently available under specific research criteria, accessibility remains limited. Enrollment delays are possible due to the newness of the frontline fecal transplant approach, requiring increased awareness among providers and patients. Despite these challenges, fecal transplantation itself is considered safe, with stable resources to expand its availability in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
